Floatz logo

Teclistamab

Hematological Malignancies

Janssen Pharmaceutical K.K.monoclonal_antibodyPhase 2Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

136 Active assets in the Hematological Malignancies cohort.

Asset / SponsorPhaseRating
Inno-206
OHSU Knight Cancer Institute
Phase 4BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3BBB
DEXAMETHASONE
City of Hope Medical Center
Phase 3BB
Bortezomib
OHSU Knight Cancer Institute
Phase 4BB
ALLOGENEIC, EX VIVO EXPANDED, UMBILICAL CORD BLOOD-DERIVED HEMATOPOIETIC CD133+ PROGENITOR CELLS- CULTURED FRACTION (CF)
Gamida Cell ltd
Phase 3BB

View all 50 →

Same molecule, other indications

Teclistamab is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
66 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
BB
Indicative ·
65 / 100
View asset →
plasma cell leukemiaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →